Ticker > Company >

Shilpa Medicare share price

Shilpa Medicare Ltd.

NSE: SHILPAMED BSE: 530549 SECTOR: Pharmaceuticals & Drugs  61k   172   27

813.15
-15.25 (-1.84%)
NSE: 20 Dec 04:02 PM

Price Summary

Today's High

₹ 844.3

Today's Low

₹ 799.85

52 Week High

₹ 959.5

52 Week Low

₹ 313.15

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

7951.87 Cr.

Enterprise Value

8091.29 Cr.

No. of Shares

9.78 Cr.

P/E

111.57

P/B

2.95

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  275.24

CASH

3.13 Cr.

DEBT

142.55 Cr.

Promoter Holding

44.33 %

EPS (TTM)

₹  7.29

Sales Growth

25.06%

ROE

1.26 %

ROCE

2.36%

Profit Growth

154.44 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.06%
3 Year6.42%
5 Year-14.14%

Profit Growth

1 Year-52.9%
3 Year-47.33%
5 Year-26.33%

ROE%

1 Year1.26%
3 Year0%
5 Year3.3%

ROCE %

1 Year2.36%
3 Year0.79%
5 Year4.03%

Debt/Equity

0.0665

Price to Cash Flow

989.81

Interest Cover Ratio

3.2072

CFO/PAT (5 Yr. Avg.)

1.66048637379028

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 44.33 7.90
Jun 2024 44.39 90.41
Mar 2024 50.01 90.41
Dec 2023 50.01 90.41
Sep 2023 50.01 90.41
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 144.8696 Cr.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.72241371982303.
  • The company has an efficient Cash Conversion Cycle of 77.7921 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.66048637379028.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.96846968619313.

 Limitations

  • The company has shown a poor profit growth of -25.4800278584316% for the Past 3 years.
  • The company has shown a poor revenue growth of 6.41784374112666% for the Past 3 years.
  • Company has a poor ROE of -0.00419547935880008% over the past 3 years.
  • Company has a poor ROCE of 0.786698899258323% over the past 3 years
  • Company has contingent liabilities of 655.2432 Cr.
  • The company is trading at a high PE of 111.57.
  • The company is trading at a high EV/EBITDA of 47.341.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 74.61 63.98 87.45 96.12 129.68
Total Expenditure 67.32 67.28 80.49 72.17 86.83
Operating Profit 7.29 -3.3 6.96 23.95 42.86
Other Income 22.76 22.33 23.25 31.45 21.47
Interest 5.18 2.61 2.71 1.95 1.19
Depreciation 12.67 12.39 12.29 12.3 12.02
Exceptional Items -0.21 -0.12 -3.78 -0.46 -0.47
Profit Before Tax 12 3.91 11.43 40.69 50.65
Tax 5.39 1.21 1.69 12.34 20.16
Profit After Tax 6.6 2.7 9.74 28.35 30.49
Adjusted EPS (Rs) 0.76 0.31 1.12 2.9 3.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 805.97 257.05 356.95 247.7 309.79
Total Expenditure 568.18 228.58 345.93 302.88 287.72
Operating Profit 237.79 28.47 11.02 -55.17 22.07
Other Income 18.37 37.14 51.52 79.82 93.34
Interest 4.33 6.07 9.05 20.83 17.26
Depreciation 34.96 22.28 34.82 46.55 49.61
Exceptional Items -4.54 52.95 8.81 -15.55 -10.45
Profit Before Tax 212.34 90.21 27.49 -58.28 38.09
Tax 44.15 25.12 7.33 -8.79 11.15
Net Profit 193.72 184.39 140.99 57.19 26.94
Adjusted EPS (Rs.) 20.63 7.98 2.32 -5.7 3.1

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 8.15 8.15 8.68 8.68 8.68
Total Reserves 1445.27 1629.68 2056.99 2108.9 2134.04
Borrowings 164.48 324.52 120.28 122.8 16.25
Other N/C liabilities 43.52 81.06 89.87 35.56 33.28
Current liabilities 359.86 473.98 161.65 242.71 226.34
Total Liabilities 2021.28 2517.39 2896.12 2518.66 2418.58
Assets
Net Block 517 640.9 565.78 608.93 586.33
Capital WIP 244.18 297.19 52.57 41.84 9.92
Intangible WIP 128.63 185.16 240.55 184.59 218.32
Investments 93.48 219.32 237.5 243.92 246.45
Loans & Advances 124.54 391.84 595.14 802.92 980.26
Other N/C Assets 5.76 3.1 895.15 0.2 0.38
Current Assets 907.69 779.9 309.44 636.25 376.93
Total Assets 2021.28 2517.39 2896.12 2518.66 2418.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 233.99 255.54 192.89 12.68 38.09
Adjustment -5.39 -25.46 32.64 -35.56 7.17
Changes in Assets & Liabilities -57.95 -117.1 -17.17 33.37 -30.28
Tax Paid -40.85 -43.34 -34.49 -8.41 -6.95
Operating Cash Flow 129.79 69.63 173.87 2.08 8.03
Investing Cash Flow -302.49 -238.13 -378.97 -94.83 155.82
Financing Cash Flow 170.1 255.58 97.23 87.68 -163.07
Net Cash Flow -2.59 87.08 -107.88 -5.07 0.78

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 50.01 50.01 50.01 44.39 44.33
brijgopal innani 1.35 1.35 1.35 1.20 1.20
deepak kumar innani 3.15 3.15 3.15 2.80 2.80
dharmavati bhutada 7.15 7.15 7.15 6.35 6.35
kamalkishore innani 0.19 0.19 0.19 0.17 0.17
kantadevi inani 2.93 2.93 2.93 2.60 2.60
keerti innani 0.18 0.18 0.18 0.16 0.16
keshav bhutada 2.30 2.30 2.30 2.05 2.05
madhav vishnukant bhutada... 2.30 2.30 2.30 2.05 2.05
manjulatha innani 0.18 0.18 0.18 0.16 0.16
namrata bhutada 0.03 0.03 0.03 0.02 0.02
natamal innani 1.30 1.30 1.30 1.16 1.16
om prakash inani 3.30 3.30 3.30 2.93 2.93
priya inani - - - - 0.18
ramakant innani 1.73 1.73 1.73 1.53 1.53
ravi kumar innani 4.62 4.62 4.62 4.10 4.10
sagar innani 1.15 1.15 1.15 1.02 1.02
shakuntalabai innani 1.30 1.30 1.30 1.15 1.15
suraj kumar inani - - - - 4.01
taradevi innani 1.44 1.44 1.44 1.28 1.28
triveni inani 0.34 0.34 0.34 0.30 0.30
vishnukant chaturbhuj bhu... 7.33 7.33 7.33 6.51 6.51
vishnukanta inani 1.40 1.40 1.40 1.24 1.24
vishnukanth c bhutada (hu... - - - 1.37 1.37
priya innani 0.21 0.21 0.21 0.18 -
suraj kumar innani 4.59 4.59 4.59 4.07 -
vishnukanth c bhutada 1.54 1.54 1.54 - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 49.99 49.99 49.99 55.61 55.67
akash bhanshali 1.84 1.84 1.84 1.64 1.55
bandhan core equity fund - - - - 1.74
cohesion mk best ideas su... 1.38 1.38 1.38 2.12 2.12
dovetail india fund class... 1.08 1.08 1.08 1.52 1.52
elm park fund limited - 1.38 1.38 1.23 1.23
icici prudential pharma h... - - 1.44 2.82 2.74
investor education and pr... - - 0.31 0.29 0.29
pivotal enterprises priva... 2.53 2.53 2.53 2.25 2.25
sapphire intrex limited 1.41 1.09 1.23 1.09 1.09
sbi life insurance co. lt... - - - 1.25 1.61
viral amal parikh 1.15 1.15 1.15 1.02 1.02
bandhan small cap fund - - - 1.59 -
amal n parikh 1.03 1.03 1.03 - -
abhishek khaitan - 1.01 - - -
investor education and pr... 0.30 0.31 - - -
ta fii investors limited 3.48 3.48 - - -

Ratings & Research Reports

Company Presentations

Company News

Shilpa Medicare informs about transcript of conference call 20 Nov, 12:11 PM Shilpa Medicare informs about updates 19 Nov, 2:38 PM Shilpa Medicare’s arm gets CEP from EDQM for API, Nifedipine 19 Nov, 12:42 PM Shilpa Medicare’s arm gets CEP from EDQM for API Octreotide 18 Nov, 5:38 PM Shilpa Medicare - Quaterly Results 13 Nov, 4:14 PM Shilpa Medicare - Quaterly Results 13 Nov, 4:14 PM Shilpa Medicare informs about updates 31 Oct, 2:54 PM USFDA concludes inspection at Shilpa Medicare’s Bengaluru unit 31 Oct, 12:30 PM Shilpa Medicare informs about closure of trading window 28 Sep, 3:29 PM Shilpa Medicare informs about disclosure 27 Sep, 2:58 PM Shilpa Medicare informs about revised disclosure 27 Sep, 2:46 PM Shilpa Medicare informs about appointment of CEO 19 Sep, 4:45 PM Shilpa Medicare informs about proceedings of AGM 17 Sep, 1:09 PM Shilpa Medicare secures USFDA’s approval for Bortezomib Injection 27 Aug, 2:57 PM Shilpa Medicare informs about disclosure 26 Aug, 10:56 AM Shilpa Medicare completes phase-3 clinical studies of novel product SMLNUD07 - NorUDCA 26 Aug, 10:41 AM Shilpa Medicare - Quaterly Results 8 Aug, 3:03 PM Shilpa Medicare - Quaterly Results 8 Aug, 3:03 PM Shilpa Medicare - Quaterly Results 8 Aug, 3:03 PM Shilpa Medicare’s arm gets CEP from EDQM for Ursodeoxycholic Acid API 31 Jul, 3:12 PM Shilpa Medicare’s arm receives GMP Certification from COFEPRIS-Mexico for Karnataka facility 23 Jul, 6:11 PM Shilpa Medicare’s arm receives registration approval for Adalimumab in Morocco 23 Jul, 2:23 PM Shilpa Medicare informs about certificate 11 Jul, 5:06 PM Shilpa Medicare informs about disclosure 25 Jun, 5:08 PM USFDA issues EIR to Shilpa Medicare’s Bio Analytical Laboratory 25 Jun, 3:13 PM Shilpa Medicare’s arm files first drug master file of Recombinant Human Albumin 20% 4 Jun, 5:06 PM Shilpa Medicare - Quaterly Results 23 May, 4:15 PM Shilpa Medicare - Quaterly Results 23 May, 4:15 PM Shilpa Medicare - Quaterly Results 23 May, 4:15 PM Shilpa Medicare’s marketing partner launches Pemetrexed injection 18 Apr, 12:11 PM Shilpa Medicare informs about disclosure 18 Apr, 11:12 AM AGES issues GMP certification to Shilpa Medicare’s Telangana unit 16 Apr, 6:13 PM Shilpa Medicare raises Rs 499 crore through QIP 15 Apr, 11:27 AM Shilpa Medicare gets nod to raise fund through QIP 9 Apr, 12:58 PM USFDA concludes inspection at Shilpa Medicare’s Bio Analytical Laboratory 1 Mar, 3:42 PM Shilpa Medicare informs about disclosure 26 Feb, 11:39 AM Shilpa Medicare - Quaterly Results 8 Feb, 4:10 PM Shilpa Medicare - Quaterly Results 8 Feb, 4:10 PM Shilpa Medicare - Quaterly Results 8 Feb, 4:10 PM EMA concludes inspection at Shilpa Medicare’s Bio Analytical Laboratory 7 Feb, 10:29 AM Shilpa Medicare informs about disclosure 27 Jan, 11:52 AM Shilpa Medicare informs about disclosure 19 Jan, 3:36 PM Shilpa Medicare’s Unit VI Bengaluru gets nod to manufacture Wafers 13 Dec, 9:49 AM Shilpa Medicare to sell 4% stake in Sravathi 17 Nov, 9:59 AM Shilpa Medicare - Quaterly Results 10 Nov, 2:57 PM Shilpa Medicare - Quaterly Results 10 Nov, 2:57 PM Shilpa Medicare acquires Pilnova Pharma in United States 3 Nov, 10:30 AM TGA Australia concludes GMP inspection at Shilpa Medicare’s Telangana facility 17 Oct, 2:22 PM Shilpa Medicare launches Naturally Derived Option for Treatment of Oral Mucositis in India 12 Oct, 9:50 AM Shilpa Medicare gets marketing authorization for Betahistine Dihydrochloride Orodispersible Films 4 Sep, 11:52 AM

Shilpa Medicare Stock Price Analysis and Quick Research Report. Is Shilpa Medicare an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Shilpa Medicare and its performance over the period of time. Shilpa Medicare stock price today is Rs 813.15.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Shilpa Medicare cash from the operating activity was Rs 8.0337 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Shilpa Medicare has a Debt to Equity ratio of 0.0665 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Shilpa Medicare , the EPS growth was 154.4372 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Shilpa Medicare has OPM of 7.12393628388058 % which is a bad sign for profitability.
     
  • ROE: Shilpa Medicare have a poor ROE of 1.2646 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Shilpa Medicare is Rs 813.15. One can use valuation calculators of ticker to know if Shilpa Medicare share price is undervalued or overvalued.
Last Updated on:
Brief about Shilpa Medicare

Shilpa Medicare Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Shilpa Medicare Ltd. is a renowned pharmaceutical company that has made significant strides in the healthcare industry. With its headquarters located in the city of Raichur, Karnataka, the company has built a strong foundation in manufacturing and marketing a wide range of active pharmaceutical ingredients (APIs) and formulations. Shilpa Medicare Ltd. aims to provide affordable and accessible healthcare solutions to patients globally.

Shilpa Medicare Ltd. – Share Price

The share price of Shilpa Medicare Ltd. is a key indicator for potential investors. It reflects the market's perception of the company's performance and future prospects. Our pre-built screening tools enable investors to track the historical share price movements of Shilpa Medicare Ltd. and analyze the trends over time.

Shilpa Medicare Ltd. – Balance Sheet

The balance sheet of Shilpa Medicare Ltd. provides a snapshot of the company's financial position. It showcases the company's assets, liabilities, and shareholders' equity at a specific point in time. By studying the balance sheet, long-term investors can gain insights into the company's financial stability and growth potential. Our premium features allow investors to conduct fair value calculations using tools such as DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis.

Shilpa Medicare Ltd. – Annual Report

The annual report of Shilpa Medicare Ltd. provides a comprehensive overview of the company's performance and achievements during a particular fiscal year. It includes detailed information about the company's business operations, financial statements, management discussions, and future strategies. Investors can download the annual reports from our website to gain deeper insights into Shilpa Medicare Ltd.'s activities.

Shilpa Medicare Ltd. – Dividend

Shilpa Medicare Ltd. acknowledges the value of its shareholders and has consistently rewarded them through dividends. Dividends are a portion of the company's profits distributed to shareholders as a return on their investments. The company's dividend policy, trends, and payout ratios can offer valuable information to long-term investors evaluating the attractiveness of Shilpa Medicare Ltd. as an investment opportunity.

Shilpa Medicare Ltd. – Quarterly Result

The quarterly results of Shilpa Medicare Ltd. provide a closer look at the company's financial performance and progress on a short-term basis. By analyzing the quarterly results, investors can assess the company's ability to generate revenue, manage costs, and sustain growth. Our website offers downloadable quarterly reports, allowing investors to stay updated on Shilpa Medicare Ltd.'s latest financial developments.

Shilpa Medicare Ltd. – Stock Price

Monitoring the stock price of Shilpa Medicare Ltd. is crucial for investors seeking stock analysis. Our pre-built screening tools provide access to real-time stock price data, historical price charts, and customizable technical indicators. With these tools, investors can track the movements of Shilpa Medicare Ltd.'s stock price and make informed decisions based on market trends and patterns.

Shilpa Medicare Ltd. – Price Chart

The price chart of Shilpa Medicare Ltd. enables investors to visually analyze the historical performance of the company's stock. By studying the price chart, long-term investors can identify trends, patterns, and potential buying or selling opportunities. Our website's pre-built screening tools incorporate advanced charting features to assist investors in conducting technical analysis effectively.

Shilpa Medicare Ltd. – News

Staying updated with the latest news about Shilpa Medicare Ltd. is essential for investors seeking stock analysis. Our website provides curated news articles that cover the company's recent developments, regulatory updates, partnerships, and product launches. Investors can access these news articles to gain insights into the factors that may influence Shilpa Medicare Ltd.'s stock performance.

Shilpa Medicare Ltd. – Concall Transcripts

Concall transcripts offer investors valuable information by providing a detailed record of the company's conference calls or earnings calls. These transcripts contain discussions between company management and analysts, providing insights into the company's financial results, future plans, and market outlook. Investors can download the concall transcripts from our website to gain a deeper understanding of Shilpa Medicare Ltd.'s operations and strategies.

Shilpa Medicare Ltd. – Investor Presentations

Investor presentations play a significant role in understanding a company's performance, strategies, and future growth prospects. Shilpa Medicare Ltd. provides downloadable investor presentations on our website to keep investors informed about the company's recent initiatives, financial highlights, and expansion plans. These presentations offer valuable insights to long-term investors looking for stock analysis.

Shilpa Medicare Ltd. – Promoters

Shilpa Medicare Ltd. is backed by a group of dedicated promoters who have been instrumental in shaping the company's growth and success. The promoters bring their expertise, vision, and strategic guidance to drive the company forward. Understanding the profile and background of the promoters can provide investors with valuable insights into the company's stability and growth potential.

Shilpa Medicare Ltd. – Shareholders

Shilpa Medicare Ltd. benefits from a diverse base of shareholders who have placed their trust in the company's potential for long-term growth. Monitoring the shareholder composition can provide investors with insights into the market sentiment towards Shilpa Medicare Ltd. and the level of conviction among institutional investors. Our pre-built screening tools enable investors to track changes in shareholder patterns and identify significant stakeholders.

At our website, we provide a range of tools and resources for long-term stock investors seeking comprehensive stock analysis of Shilpa Medicare Ltd. Our pre-built screening tools, downloadable annual reports, concall transcripts, investor presentations, and premium features for fair value calculations offer investors a wealth of information to make informed investment decisions.

Read More
X